Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Terry Rosen, Ph.D., will deliver a presentation on Tuesday, January 14th, 2025, at 3:45pm PT. The presentation will be accessible via live webcast through the 'Investors & Media' section of the company's website, with a replay option available after the event.
Arcus Biosciences (NYSE:RCUS), un'azienda biofarmaceutica in fase clinica specializzata in terapie oncologiche, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference che si terrà a San Francisco. Il CEO Terry Rosen, Ph.D., presenterà una relazione il martedì 14 gennaio 2025, alle 15:45 PT. La presentazione sarà accessibile tramite webcast dal vivo nella sezione 'Investitori & Media' del sito web dell'azienda, con un'opzione di replay disponibile dopo l'evento.
Arcus Biosciences (NYSE:RCUS), una compañía biofarmacéutica en etapa clínica especializada en terapias contra el cáncer, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan en San Francisco. El CEO Terry Rosen, Ph.D., realizará una presentación el martes 14 de enero de 2025, a las 3:45 p.m. PT. La presentación será accesible a través de una transmisión en vivo en la sección 'Inversores y Medios' del sitio web de la compañía, con una opción de repetición disponible después del evento.
Arcus Biosciences (NYSE:RCUS), 암 치료를 전문으로 하는 임상 단계의 생명공학 회사가 샌프란시스코에서 열리는 제43회 연례 J.P. Morgan Healthcare Conference에 참여한다고 발표했습니다. CEO 테리 로젠, Ph.D.가 2025년 1월 14일 화요일 오후 3시 45분 PT에 발표를 진행할 예정입니다. 이 발표는 회사 웹사이트의 '투자자 및 미디어' 섹션을 통해 실시간 웹캐스트로 시청할 수 있으며, 이벤트 후 재생 옵션도 제공됩니다.
Arcus Biosciences (NYSE:RCUS), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapeutiques contre le cancer, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare à San Francisco. Le PDG Terry Rosen, Ph.D., fera une présentation le mardi 14 janvier 2025, à 15h45 PT. La présentation sera accessible en direct via un webinaire dans la section 'Investisseurs & Médias' du site Web de l'entreprise, avec une option de rediffusion disponible après l'événement.
Arcus Biosciences (NYSE:RCUS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Krebstherapeutika spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco angekündigt. CEO Terry Rosen, Ph.D., wird am Dienstag, den 14. Januar 2025, um 15:45 Uhr PT eine Präsentation halten. Die Präsentation wird über einen Live-Stream im Bereich 'Investoren & Medien' der Unternehmenswebsite zugänglich sein, und es wird eine Wiederholungsoption nach der Veranstaltung geben.
- None.
- None.
A live webcast of the presentation will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219599177/en/
Investor Inquiries
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
When is Arcus Biosciences (RCUS) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Arcus Biosciences' (RCUS) J.P. Morgan Healthcare Conference presentation?
Who will represent Arcus Biosciences (RCUS) at the 2025 J.P. Morgan Healthcare Conference?
What is the focus of Arcus Biosciences' (RCUS) research and development?
